Luca Issi
Stock Analyst at RBC Capital
(1.35)
# 3,420
Out of 4,876 analysts
199
Total ratings
36%
Success rate
-13.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.32 | +72.41% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.18 | +747.46% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $17.43 | +3.27% | 7 | May 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $32 → $28 | $27.16 | +3.09% | 14 | May 2, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $205 → $210 | $172.14 | +21.99% | 2 | May 2, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $4.12 | +385.44% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $322.83 | +2.22% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $12.03 | +689.69% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.54 | +269.75% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $9.22 | +84.38% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.61 | +96.67% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $11.30 | +32.74% | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $3.84 | +811.46% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $16.80 | +54.76% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $39.80 | +75.88% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $55.17 | +26.88% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $47.49 | +1.07% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $16.08 | +161.19% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $13.86 | +73.16% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $34.01 | +67.60% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.39 | +257.57% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $29.03 | +130.80% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $9.57 | +370.22% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.28 | +75.44% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $36.52 | +110.84% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $6.67 | +124.89% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $9.56 | +464.85% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.26 | +1,011.11% | 5 | Aug 7, 2024 |
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.32
Upside: +72.41%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.18
Upside: +747.46%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $17.43
Upside: +3.27%
Moderna
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $27.16
Upside: +3.09%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $205 → $210
Current: $172.14
Upside: +21.99%
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.12
Upside: +385.44%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $322.83
Upside: +2.22%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $12.03
Upside: +689.69%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.54
Upside: +269.75%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $9.22
Upside: +84.38%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.61
Upside: +96.67%
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $11.30
Upside: +32.74%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $3.84
Upside: +811.46%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $16.80
Upside: +54.76%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $39.80
Upside: +75.88%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $55.17
Upside: +26.88%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $47.49
Upside: +1.07%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $16.08
Upside: +161.19%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $13.86
Upside: +73.16%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $34.01
Upside: +67.60%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $8.39
Upside: +257.57%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $29.03
Upside: +130.80%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $9.57
Upside: +370.22%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.28
Upside: +75.44%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $36.52
Upside: +110.84%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $6.67
Upside: +124.89%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $9.56
Upside: +464.85%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.26
Upside: +1,011.11%